Findings

What do systematic reviews say?

4,860 questions · 64,864 findings · 4,913 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 21.4%GRADE not reported 3,491 · 5.4%Very low 16,300 · 25.1%Low 17,338 · 26.7%Moderate 10,900 · 16.8%High 2,966 · 4.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Oral factor Xa inhibitors vs conventional anticoagulation

Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.92 [0.66, 1.29]
3 studies · 8186 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.83 [0.66, 1.03]
8 studies · 11416 participants
Moderate

Oral factor Xa inhibitors vs conventional anticoagulation

DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques

Oral factor Xa inhibitors showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).

1 finding from 1 review

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of… 2023 · Cochrane Headline outcomes only
OR 0.77 [0.48, 1.25]
2 studies · 8151 participants
Moderate

Perampanel add‐on vs placebo

50% or greater reduction in seizure frequency · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on leads to higher ≥ 50% reduction in seizure frequency compared with placebo (high certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 1.67 [1.43, 1.95]
7 studies · 2524 participants
High

Perampanel add‐on vs placebo

Seizure freedom · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher seizure freedom compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 2.5 [1.38, 4.54]
5 studies · 2323 participants
Low

Perampanel add‐on vs placebo

Acceptability ‐ total dropouts · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 1.3 [1.03, 1.63]
7 studies · 2524 participants
Low

Perampanel add‐on vs placebo

Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 2.36 [1.59, 3.51]
7 studies · 2524 participants
Low

Perampanel add‐on vs placebo

Proportion of participants who experienced ≥ 1 adverse effect · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 1.17 [1.1, 1.24]
7 studies · 2524 participants
High

Perampanel add‐on vs placebo

Proportion of participants who experienced ataxia · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 14.32
2 studies · 1098 participants
Low

Perampanel add‐on vs placebo

Dizziness · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher proportion of participants who experienced dizziness compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 2.87
7 studies · 2524 participants
Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1061 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1139 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1134 participants
High